- Home
- THAR
THAR
Tharimmune Inc.
as 04-25-2025 4:00pm EST
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 2.4M | IPO Year: | 2022 |
| Target Price: | $17.00 | AVG Volume (30 days): | 97.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $6.45 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tharimmune Inc. News
THAR Breaking Stock News: Dive into THAR Ticker-Specific Updates for Smart Investing
ACCESS Newswire
11 days ago
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
ACCESS Newswire
19 days ago
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
ACCESS Newswire
a month ago
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
ACCESS Newswire
a month ago
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
ACCESS Newswire
2 months ago
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
ACCESS Newswire
3 months ago
Tharimmune to Present at the Microcap Conference 2025
ACCESSWIRE
4 months ago
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
ACCESSWIRE
5 months ago
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Compare THAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THAR Tharimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.